Fine mapping MHC associations in Graves' disease and its clinical subtypes in Han Chinese.

Fine mapping MHC associations in Graves' disease and its clinical subtypes in Han Chinese.
复制标题

汉族格雷夫斯病及其临床亚型中 MHC 关联的精细定位。

DOI:
10.1136/jmedgenet-2017-105146
复制
发表时间:
2018-10
影响因子:
4
通讯作者:
Huang W
Huang W
中科院分区:
医学1区
文献类型:
--
作者:
Chu X;Yang M;Song ZJ;Dong Y;Li C;Shen M;Zhu YQ;Song HD;Chen SJ;Chen Z;Huang W

文献摘要

参考文献

被引文献

相似文献

经典人类白细胞抗原(HLA)基因是格雷夫斯病(GD)最重要的遗传决定因素。该研究的目的是精细绘制 HLA 基因的因果变异图谱。我们应用泛亚 HLA 参考组进行插补,深入研究 1468 名 GD 患者和 1490 名汉族对照者中主要组织相容性复合体 (MHC) 与 GD 的关联,直至经典 HLA 基因的氨基酸水平。 HLA 基因中最强的发现是与 HLA-DPβ1 位置 205 (Pomnibus=2.48×10−33) 的关联。 HLA-DPA1*02:02是经典HLA等位基因中最强的关联,与HLA-DPα1残基Met11完全连锁不平衡(OR=1.90,Pbinary=1.76×10−31)。应用逐步条件分析,我们确定了 HLA-DPβ1 中的第 205 位氨基酸、HLA-B 中的第 66 和 99 位氨基酸以及 HLA-DRβ1 中的第 28 位氨基酸解释了 MHC 与 GD 风险的大部分关联。我们进一步评估了抗甲状腺药物治疗后两种临床亚型GD的风险,即持续性促甲状腺激素受体抗体阳性(pTRAb+)组和“非持续性TRAb阳性”(pTRAb−)组。我们发现HLA-B残基Lys66-Arg69-Val76可以单独驱动pTRAb−GD风险,而HLA-DPβ1位置205、HLA-B位置69和199以及HLA-DRβ1位置28驱动pTRAb+GD 风险。 pTRAb+ 和 pTRAb− GD 之间的风险异质性可能是由 HLA-DPα1 Met11 驱动的。四个氨基酸位置可以解释汉族人 MHC 与 GD 的关联。这些不同的 HLA 关联模式表明这两种亚型具有不同的发病分子机制。
The classical human leucocyte antigen (HLA) genes were the most important genetic determinant for Graves’ disease (GD). The aim of the study was to fine map causal variants of the HLA genes. We applied imputation with a Pan-Asian HLA reference panel to thoroughly investigate themajor histocompatibility complex (MHC) associations with GD down to the amino acid level of classical HLA genes in 1468 patients with GD and 1490 controls of Han Chinese. The strongest finding across the HLA genes was the association with HLA-DPβ1 position 205 (Pomnibus=2.48×10−33). HLA-DPA1*02:02 was the strongest association among the classical HLA alleles, which was in perfect linkage disequilibrium with HLA-DPα1 residue Met11 (OR=1.90, Pbinary=1.76×10−31). Applying stepwise conditional analysis, we identified amino acid position 205 in HLA-DPβ1, position 66 and 99 in HLA-B and position 28 in HLA-DRβ1 explain majority of the MHC association to GD risk. We further evaluated risk of two clinical subtypes of GD, namely persistent thyroid stimulating hormone receptor antibody -positive (pTRAb+) group and ‘non-persistent TRAb positive’ (pTRAb−) group after antithyroid drug therapy. We found that HLA-B residues Lys66-Arg69-Val76 could drive pTRAb− GD risk alone, while HLA-DPβ1 position 205, HLA-B position 69 and 199 and HLA-DRβ1 position 28 drive pTRAb+ GD risk. The risk heterogeneity between pTRAb+ and pTRAb− GD might be driven by HLA-DPα1 Met11. Four amino acid positions could account for the associations of MHC with GD in Han Chinese. These distinct HLA association patterns indicated the two subtypes have distinct molecular mechanisms of pathogenesis.
DOI: 10.3389/fendo.2016.00120
发表时间: 2016
影响因子: 5.2
作者:
Inaba H;De Groot LJ;Akamizu T
通讯作者: Akamizu T
DOI: 10.1210/jc.2005-2537
发表时间: 2006-06-01
影响因子: 5.8
作者:
Inaba, Hidefumi;Martin, William;De Groot, Leslie J.
通讯作者: De Groot, Leslie J.
DOI: 10.1507/endocrj.k10e-262
发表时间: 2011-02-01
期刊: ENDOCRINE JOURNAL
影响因子: 2
作者:
Konishi, Toshiaki;Okamoto, Yasuyuki;Hamada, Noboru
通讯作者: Hamada, Noboru
DOI: 10.1016/0198-8859(92)90101-r
发表时间: 1992-11-01
期刊: HUMAN IMMUNOLOGY
影响因子: 2.7
作者:
DONG, RP;KIMURA, A;SASAZUKI, T
通讯作者: SASAZUKI, T
DOI: 10.1016/0198-8859(94)90260-7
发表时间: 1994-03-01
期刊: HUMAN IMMUNOLOGY
影响因子: 2.7
作者:
ONUMA, H;OTA, M;INOKO, H
通讯作者: INOKO, H